Results 151 to 160 of about 280,511 (259)

Interferon signaling and ferroptosis in tumor immunology and therapy. [PDF]

NPJ Precis Oncol
Hu W, Zhao Z, Du J, Jiang J, Yang M, Tian M, Zhao P.   +6 more
europepmc   +1 more source

Organoid Models of Tumor Immunology. [PDF]

Trends Immunol, 2020
Yuki K, Cheng N, Nakano M, Kuo CJ.
europepmc   +1 more source

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Advanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer, Ian de Ridder, Mahjoobeh Ehsani, Marasim Khan, Justin Kale, Lukas P. Frenzel, David Andrews, Spyridoula Karamanou, Ana J. Garcia‐Saez, Geert Bultynck   +9 more
wiley   +1 more source

Dynamic Tumor Immunology-on-a-Chip for Peripheral Blood-Derived Tumor-Reactive T Cell Expansion. [PDF]

Research (Wash D C)
Shou X, Yu Y, Wu D, Lu P, Zhao M, Zhao Y.   +5 more
europepmc   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

Case Report: Multimodal immunotherapeutic regimen (envafolimab + chemotherapy + radiotherapy) for four synchronous primary malignant neoplasms: a case report of 33-month survival and implications for tumor immunology. [PDF]

Front Oncol
Liu Y, Zhang Y, Zhang Y, Duan X, Gao Z, Zhang X, Zhao J.   +6 more
europepmc   +1 more source

Immediate Growth Control in Response to Boiling Histotripsy is Prognostic for Intratumoral Immune Activation

Advanced Science, EarlyView.
Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger, Matthew R. DeWitt, Carly M. Van Wagoner, Claire A. Conarroe, Charles C. Funk, Aaron B. Streit, AeRyon Kim, Richard J. Price, Timothy N. J. Bullock   +8 more
wiley   +1 more source

Investigating the correlation between tertiary lymphoid structures and clinical outcomes in pancreatic ductal adenocarcinoma: insights into tumor immunology. [PDF]

Front Oncol
Hu L, Xiao Y, Jiang N, Hu Y, Qiu L, Geng B.   +5 more
europepmc   +1 more source

The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. [PDF]

Front Immunol, 2020
Fang Z, Jiang C, Li S.
europepmc   +1 more source

Engineering‐Modulated Molybdenum Enzymes Strategy for Tumor‐Specific Metabolic‐Immunotherapy

Advanced Science, EarlyView.
Biodegradable molybdenum sulfide nanoparticles were synthesized via a one‐pot strategy to increase molybdenum enzyme activity and thus effectively potentiate anti‐tumor immunity by integrating molybdenum‐based metalloimmunotherapy with hydrogen sulfide gas therapy.
Xiaoxiao Pan, Zifan Pei, Jie Wu, Nan Jiang, Qian Li, Yuqi Yang, Jie Cao, Yechen Huang, Shumin Sun, Qialu Du, Zhicheng Liu, Lin Zhang, Fei Gong, Jinhua Zhou, Liang Cheng   +14 more
wiley   +1 more source